Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Andrea B ApoloKarla V BallmanGuru SonpavdeStephanie BergWilliam Y KimRahul ParikhMin Yuen TeoRandy F SweisDaniel M GeynismanPetros GrivasGurkamal ChattaZachery Roger ReichertJoseph W KimMehmet Asim BilenBradley McGregorParminder SinghAbhishek TripathiSuzanne ColeNicholas SimonScot NiglioLisa LeyLisa CordesSandy SrinivasJiaoti HuangMeagan OdegaardColleen WattDaniel PetrylakJeannie Hoffman-CensitsYujia WenOlwen HahnCecilia MitchellAlan TanHoward StreicherElad SharonHelen MoonMichael WoodsSusan HalabiGabriela Perez BurbanoMichael J MorrisJonathan E RosenbergPublished in: The New England journal of medicine (2024)
Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation. (Funded by the National Cancer Institute of the National Institutes of Health and others; Alliance A031501 AMBASSADOR ClinicalTrials.gov number, NCT03244384.).
Keyphrases
- free survival
- early stage
- skeletal muscle
- advanced non small cell lung cancer
- minimally invasive
- healthcare
- public health
- coronary artery bypass
- mental health
- quality improvement
- health information
- surgical site infection
- coronary artery disease
- atrial fibrillation
- climate change
- percutaneous coronary intervention